FDA Approved Anti-Obesity Medications

Glucagon-like peptite-1 receptor agonist that is an injectable drug. Semaglutideis used at doses up to 2.0 mg weekly for type 2 diabetes. Semaglutide 2.4 mg weekly is approved for treatment of obesity. Average weight loss at one year is 16%.

Glucagon-like peptide-1 receptor agonist that is an injectable drug. At lower doses (1.8 mg per day), liraglutide is indicated to lower blood sugar among patients with type 2 diabetes mellitus. Liraglutide 3.0 mg per day is approved for treatment of obesity. Some patients may lose 5 –10% of body weight, especially with the liraglutide higher dose.

Gastrointestinal lipase inhibitor that impairs digestion of dietary fat.Lower doses are approved over-the-counter. Some patients may lose about 5% of body weight.

Sympathomimetic amine approved in 1959. It is a DEA Schedule IV stimulant agent approved for short-term use (12 weeks). Some patients may lose about 5% of body weight.

Combination of naltrexone (opioid antagonist used for addictions) and bupropion (used for depression and smoking cessation). Some patients may lose 5 -10% of body weight.

Combination of Methionine, Inositol, Choline and B12. These are lipotropic agents that help breakdown fat, during metabolism, by increasing overall energy.

GET YOUR SAVINGS CARD HERE ~https://www.enrollment.zepbound.lilly.com/enroll/checkEnrollment ~ Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. It works by acting like GLP-1 and GIP, two hormones that your gut releases into the body. These hormones are thought to play a role in controlling your appetite, by making you feel more full and less hungry.

Combination of phentermine (sympathomimetic amine, anti-obesity drug) and topiramate (used to treat seizures and migraine headaches). DEA Schedule IV drug. Some patients may lose an average of 5 –10% of body weight.